Category: Tengion Inc.
Tengion posts greater losses during the 2nd quarter as it develops its human organ transplant technology, but rakes in more than $30M in investments.
Tengion (NSDQ:TNGN) almost tripled its losses in the 2nd quarter, but raked in more than $30 million in investments for its human organ regeneration technology.
Tengion Inc. raises $74.3 million to back its Neo-Kidney Augment and Neo-Urinary Conduit clinical programs.
Tengion (NSDQ:TNGN) said it raised $74.3 million from 22 unnamed investors as it puts a pair of clinical programs through their paces.
The Winston-Salem, N.C.-based medical device company is developing the Neo-Kidney Augment and Neo-Urinary Conduit, human organs that are grown using a bioabsorbable scaffold and patients' own cells.
Tengion Inc. raises $33.6 million from a pair of investors supporting its Neo-Kidney Augment and Neo-Urinary Conduit clinical programs.
North Carolina regenerative medicine company Tengion (NSDQ:TNGN) raised $33.6 million in support of clinical studies of its leading programs, the Neo-Kidney Augment and Neo-Urinary Conduit programs. TNGN shares jumped 15.3% to 68¢ around 12:40 p.m. today, up from an opening price of 64¢.
Tengion's clinical trial of its Neo-Urinary Conduit system will continue after 2 of the 6 enrolled patients died from causes unrelated to the trial.
Tengion (NSDQ:TNGN) plans to complete enrollment its in Neo-Urinary Conduit clinical trial following the deaths of 2 of the 6 enrolled patients after deeming the deaths unrelated to the device or surgical procedure.
Medtronic touts news study results comparing its Resolute drug-eluting stent in patients with and without diabetes; also, Tengion struggles, but may find refuge in Medtronic; Uroplasty soars on 40% boost in Q4 sales; NeuroMetrix targets investors; Allscripts shareholders launch proxy war; plus, a Funding Roundup and analysts' ups and downs.
Medtronic (NYSE:MDT) touted new study results for its Resolute drug-eluting stents, the 1st with FDA indication for treatment of patients with diabetes.
Abbott gets FDA nod for advanced femtosecond laser for cataract surgery, St. Jude Medical launches next-gen Trifecta heart valve in Japan, NeuroMetrix files 510(k) for Sensus neurostimulator for pain management, and more.
Abbott gets FDA nod for advanced femtosecond laser for cataract surgery
, Carestream Health Inc.
, Devicor Medical Products
, ITGI Medical Ltd.
, NLT Spine
, Revolutions Medical Corp.
, St. Jude Medical
, Tengion Inc.
, Abbott Laboratories
Bovie Medical swings to 2011 black
Bovie Medical Corp.
, Cambridge Heart Inc.
, Daxor Corp.
, Dehaier Medical Systems Ltd.
, Derma Sciences Inc.
, Echo Therapeutics Inc.
, EDAP TMS SA
, Guided Therapeutics Inc.
, Kips Bay Medical Inc.
, Lumenis Ltd.
, Mazor Robotics Ltd.
, Nephros Inc.
, Non-Invasive Monitoring Systems Inc.
, Patient Safety Technologies Inc.
, Response Biomedical Corp.
, SANUWAVE Health Inc.
, Stereotaxis Inc.
, Tengion Inc.
, Vasomedical Inc.
, Young Innovations